天津力生制药股份有限公司 关于部分限制性股票回购注销完成暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 重要提示： 1.本次回购注销的限制性股票授予日为2022年12月27日和2025年2月26日，本次回购 注销限制性股票数量共计88,140股，占回购前公司总股本257,704,999股的0.0342%，回购 价格分别为2022年首次授予8.76元/股和2024年首次授予10.24元/股。 2.截至2025年10月28日，上述限制性股票已在中国证券登记结算有限责任公司深圳分 公司办理完回购注销相关手续。 一、公司股权激励计划简述及实施情况 （一）2022年股权激励计划 1.2022年10月28日，公司召开第七届董事会第十五次会议，会议审议通过了《关于公 司2022年限制性股票激励计划（草案）及其摘要的议案》《关于公司2022年限制性股票激 励计划实施考核管理办法的议案》以及《关于提请公司股东大会授权董事会办理2022年限 制性股票激励计划相关事宜的议案》等议案。公司独立董事就本激励计划相关议案发表了 同意的独立意见。 证券代码：002393 ...

Core Insights - The company reported a slight decline in revenue for the first three quarters of 2025, with total revenue at 1.007 billion yuan, a year-on-year decrease of 1.61% [1] - Net profit attributable to shareholders saw a significant increase of 119.05%, reaching 371 million yuan, indicating strong profitability growth [1] - Basic earnings per share improved to 1.44 yuan, reflecting a substantial increase compared to the same period last year [1] Financial Performance - The net profit growth of 119.05% was primarily driven by non-recurring gains and continuous optimization of core business operations [1] - Excluding non-recurring items, the net profit was 127 million yuan, marking a year-on-year increase of 19.21%, demonstrating stable profitability in core operations [1] - The company achieved a net profit of 343 million yuan in the first half of the year, a remarkable increase of 235.04%, with the third quarter net profit approximately 28 million yuan, continuing the strong growth trend [1] - Operating cash flow net amount was 125 million yuan, up 35.98% year-on-year, indicating improved operational efficiency and enhanced collection capabilities [1] Research and Development - Research and development investment exceeded 60 million yuan in the first three quarters, facilitating the approval of multiple generic drugs and consistency evaluation products, including Cefaclor sustained-release tablets and Voriconazole [2] - The company is deepening its "industry + capital" dual-drive strategy, with over 300 quality merger and acquisition projects in reserve to strengthen its industry chain layout [2] - Initiatives such as reshaping distribution channels and reclaiming core product general agency rights have been implemented to enhance market control [2]

Macro Highlights - The main goals for the "14th Five-Year Plan" period include significant achievements in high-quality development, substantial improvement in technological self-reliance, breakthroughs in comprehensive reforms, enhanced social civilization, improved quality of life, major progress in building a beautiful China, and a more solid national security barrier [1] - By 2035, the aim is to significantly elevate China's economic, technological, defense, and comprehensive national strength, with per capita GDP reaching the level of moderately developed countries, leading to a happier and better life for the people and basic realization of socialist modernization [1] Trade Relations - The Ministry of Commerce announced that a Chinese delegation led by Vice Premier He Lifeng will engage in economic and trade consultations with the U.S. in Malaysia from October 24 to 27, focusing on important issues in Sino-U.S. economic relations [1] EU Sanctions Response - The Ministry of Commerce expressed strong dissatisfaction and firm opposition to the EU's decision to sanction Chinese companies, including large oil refineries and traders, during the 19th round of sanctions against Russia, emphasizing the need to protect the legitimate rights and interests of Chinese enterprises [2] State-Owned Enterprises Planning - The State-owned Assets Supervision and Administration Commission held a meeting to discuss the "14th Five-Year Plan" for central enterprises, emphasizing the need to align with the strategic mission assigned by the Party Central Committee and to enhance core functions and competitiveness [3] - The meeting highlighted the importance of optimizing layout and structural adjustments in line with national needs and industry trends, and improving the quality of planning through thorough research and unified thinking [3] Foreign Exchange Management - The Deputy Director of the State Administration of Foreign Exchange encouraged the implementation of innovative and integrated exploratory policies in Shanghai, focusing on the use of AI and big data to enhance foreign exchange services [4] - The aim is to improve the cross-border financial service capabilities of Shanghai while balancing financial openness and security [4] Company News - Huagong Technology reported a 40.92% year-on-year increase in net profit for the first three quarters and is planning to issue H-shares for listing in Hong Kong [8] - Yangjie Technology terminated its acquisition of 100% equity in Better Electronics [8] - Xinda Securities received approval for the issuance of up to 10 billion yuan in technology innovation corporate bonds [8] - Shuangliang Energy plans to raise no more than 1.292 billion yuan for projects related to zero-carbon intelligent manufacturing [8] - New Lai Materials' subsidiary plans to invest 2 billion yuan in semiconductor core component projects [8] - Chuanfa Longmang's subsidiary intends to invest 366 million yuan in a 100,000 tons/year lithium dihydrogen phosphate project [8] - Steel Research High-tech plans to establish a subsidiary and new industrial base in Saudi Arabia [8] - Aote Electronics intends to terminate the smart integration project for intelligent outlets [8] - Shengyi Electronics expects a year-on-year net profit increase of 476% to 519% for the first three quarters [8] - Other companies reported significant year-on-year net profit growth, including Tianeng Heavy Industry (1359.03%), Te Yi Pharmaceutical (985.18%), and Zhuanlei Technology (598.09%) [8][9]

Core Viewpoint - Tianjin Development (00882.HK) announced that Lifesun Pharmaceutical (002393.SZ) achieved a revenue of 1.007 billion yuan in the first three quarters of 2025, reflecting a year-on-year decrease of 1.61% while net profit attributable to shareholders increased by 119.05% to 370 million yuan [1] Financial Performance - Lifesun Pharmaceutical's revenue for the first three quarters of 2025 was 1.007 billion yuan, down 1.61% year-on-year [1] - The net profit attributable to shareholders reached 370 million yuan, showing a significant increase of 119.05% compared to the previous year [1] - The net profit excluding non-recurring gains and losses was 127 million yuan, which represents a year-on-year growth of 19.21% [1] - Basic earnings per share were reported at 1.44 yuan [1]

Core Viewpoint - Tianjin Development (00882) announced that its indirect non-wholly-owned subsidiary, Tianjin Lisheng Pharmaceutical (002393), reported a total revenue of 1.007 billion yuan for the nine months ending September 30, 2025, representing a year-on-year decrease of 1.61% while the net profit attributable to the parent company increased by 119.05% to 371 million yuan, with basic earnings per share of 1.44 yuan [1] Financial Performance - Total revenue for Tianjin Lisheng Pharmaceutical for the nine months was 1.007 billion yuan, down 1.61% year-on-year [1] - Net profit attributable to the parent company reached 371 million yuan, marking a significant increase of 119.05% compared to the previous year [1] - Basic earnings per share stood at 1.44 yuan [1]

Core Viewpoint - Tianjin Development (00882) reported a mixed financial performance for its indirect non-wholly owned subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd., with a slight decline in revenue but a significant increase in net profit [1] Financial Performance - Total revenue for the nine months ending September 30, 2025, was 1.007 billion yuan, representing a year-on-year decrease of 1.61% [1] - Net profit attributable to the parent company's owners was 371 million yuan, showing a year-on-year increase of 119.05% [1] - Basic earnings per share stood at 1.44 yuan [1]

Group 1 - The company announced the election of Ms. Wang Qian as the employee director of the eighth board of directors [2] - The term of the newly elected director will last until the end of the eighth board's term [2]

（文章来源：证券日报） 证券日报网讯 10月23日晚间，力生制药发布公告称，公司第七届董事会任期已届满。根据有关规定， 公司将按照相关程序进行董事会换届选举。公司于2025年10月22日召开第七届董事会第五十三次会议审 议通过了《关于选举第八届董事会非独立董事的议案》《关于选举第八届董事会独立董事的议案》，经 公司第七届董事会提名委员会审查，公司董事会同意提名张平先生、滕飞先生、王福军先生、段爽女士 和卢小曼女士为第八届董事会非独立董事候选人；同意提名雷英女士、魏东芝先生和张梅女士为公司第 八届董事会独立董事候选人。 ...

Core Viewpoint - Lisheng Pharmaceutical reported a slight decline in revenue for the first three quarters of 2025, but a significant increase in net profit and earnings per share, indicating strong profitability despite revenue challenges [1] Financial Performance - Revenue for the first three quarters of 2025 was approximately 1.007 billion yuan, a year-on-year decrease of 1.61% [1] - Net profit attributable to shareholders was about 371 million yuan, reflecting a year-on-year increase of 119.05% [1] - Basic earnings per share reached 1.44 yuan, up 118.18% year-on-year [1] Market Position - As of the report date, Lisheng Pharmaceutical's market capitalization stood at 6.1 billion yuan [1]

2025年1至6月份，力生制药的营业收入构成为：制药业占比100.0%。 每经AI快讯，力生制药（SZ 002393，收盘价：23.65元）10月23日晚间发布公告称，公司第七届第五十 三次董事会会议于2025年10月22日以通讯表决方式召开。会议审议了《关于选举公司第八届董事会独立 董事的议案》等文件。 每经头条（nbdtoutiao）——四次登上央视，知名大佬"消失"5年，我们在水果仓库找到了他！从月薪 5000到千亿市值公司联席总裁，他45岁再创业 截至发稿，力生制药市值为61亿元。 （记者 王瀚黎） ...